Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 1, 2026, 7:24 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 116 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: LBH589 Clear all
Terminated Phase 1 Interventional

Safety of LBH589 Alone and in Combination With IV Docetaxel and Prednisone

NCT00493766
View directory record Official record
Conditions
Hormone Refractory Prostate Cancer
Interventions
LBH589
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2006
U.S. locations
5
States / cities
Boston, Massachusetts • St Louis, Missouri • Las Vegas, Nevada + 2 more
Source: ClinicalTrials.gov public record
Updated Dec 18, 2020 · Synced Sep 1, 2026, 7:24 PM EDT
Completed Phase 1 Interventional

Study of Panobinostat in Combination With Sorafenib in Kidney, Soft Tissue or Lung Cancers

NCT01005797
View directory record Official record
Conditions
Renal Cancer, Non Small Cell Lung Cancer (NSCLC), Soft Tissue Sarcoma
Interventions
Panobinostat (LBH589), Sorafenib
Drug
Lead sponsor
Medical University of South Carolina
Other
Eligibility
18 Years and older
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2017
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Mar 2, 2017 · Synced Sep 1, 2026, 7:24 PM EDT
Completed Phase 1Phase 2 Interventional Results available

LBH589 Plus Decitabine for Myelodysplastic Syndromes (MDS) or Acute Myeloid Leukemia (AML)

NCT00691938
View directory record Official record
Conditions
Leukemia, Myeloid, Acute, Myelodysplastic Syndromes
Interventions
LBH589, Decitabine
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
60 Years and older
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2014
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Oct 12, 2016 · Synced Sep 1, 2026, 7:24 PM EDT
Completed Phase 1 Interventional

Study of Cisplatin and Pemetrexed in Combination With Panobinostat in Solid Tumors

NCT01336842
View directory record Official record
Conditions
Solid Tumors, Non-Small Cell Lung Cancer (NSCLC)
Interventions
Panobinostat, Cisplatin, Pemetrexed
Drug
Lead sponsor
University of California, Davis
Other
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2017
U.S. locations
2
States / cities
Sacramento, California • Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Jan 8, 2018 · Synced Sep 1, 2026, 7:24 PM EDT
Terminated Phase 2 Interventional Results available

Panobinostat & Bortezomib in Pancreatic Cancer Progressing on Gemcitabine Therapy

NCT01056601
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
Bortezomib, Panobinostat
Drug
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Dec 27, 2017 · Synced Sep 1, 2026, 7:24 PM EDT
Terminated Phase 1 Interventional

A Study of Intra-tumoral Administered MTX110 in Patients With Recurrent Glioblastoma

NCT05324501
View directory record Official record
Conditions
Recurrent Glioblastoma
Interventions
MTX110, Programmable pump and catheter system
Drug · Device
Lead sponsor
Biodexa Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
2
States / cities
Jacksonville, Florida • Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 9, 2025 · Synced Sep 1, 2026, 7:24 PM EDT
Completed Phase 1 Interventional

A Dose Finding Study With I.V. Panobinostat (LBH589), Docetaxel, and Prednisone in Patients With Hormone Refractory Prostate Cancer

NCT00663832
View directory record Official record
Conditions
Prostate Cancer
Interventions
LBH589 (i.v. panobinostat)
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older · Male only
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2008
U.S. locations
7
States / cities
Rockville, Maryland • Detroit, Michigan • St Louis, Missouri + 4 more
Source: ClinicalTrials.gov public record
Updated Dec 18, 2020 · Synced Sep 1, 2026, 7:24 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

Panobinostat and Everolimus in Treating Patients With Metastatic or Unresectable Renal Cell Cancer That Does Not Respond to Treatment With Sunitinib Malate or Sorafenib Tosylate

NCT01582009
View directory record Official record
Conditions
Clear Cell Renal Cell Carcinoma, Recurrent Renal Cell Cancer, Stage III Renal Cell Cancer, Stage IV Renal Cell Cancer
Interventions
panobinostat, everolimus, laboratory biomarker analysis, pharmacological study, liquid chromatography, mass spectrometry, enzyme-linked immunosorbent assay, immunohistochemistry staining method
Drug · Other
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
2
States / cities
Buffalo, New York • Rochester, New York
Source: ClinicalTrials.gov public record
Updated Aug 14, 2022 · Synced Sep 1, 2026, 7:24 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Safety and Efficacy Studies of Panobinostat and Bicalutamide in Patients With Recurrent Prostate Cancer After Castration

NCT00878436
View directory record Official record
Conditions
Prostate Cancer, Prostatic Neoplasms
Interventions
Panobinostat, Bicalutamide
Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years and older · Male only
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
4
States / cities
New Brunswick, New Jersey • Lake Success, New York • New York, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 6, 2018 · Synced Sep 1, 2026, 7:24 PM EDT
Completed No phase listed Observational

A Disease Registry Encompassing the Care Of Patients With Multiple Myeloma on Panobinostat

NCT04150289
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Farydak
Drug
Lead sponsor
pharmaand GmbH
Industry
Eligibility
18 Years and older
Enrollment
248 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
7
States / cities
Indianapolis, Indiana • Las Vegas, Nevada • Charlotte, North Carolina + 4 more
Source: ClinicalTrials.gov public record
Updated Jun 14, 2023 · Synced Sep 1, 2026, 7:24 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Study of the Combination of Panobinostat and Carfilzomib in Patients With Relapsed/Refractory Multiple Myeloma

NCT01496118
View directory record Official record
Conditions
Multiple Myeloma
Interventions
panobinostat, carfilzomib
Drug
Lead sponsor
SCRI Development Innovations, LLC
Other
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2020
U.S. locations
13
States / cities
Denver, Colorado • Fort Myers, Florida • Pensacola, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Feb 1, 2022 · Synced Sep 1, 2026, 7:24 PM EDT
Terminated Phase 1 Interventional

Panobinostat With Fludarabine and Cytarabine for Treatment of Children With Acute Myeloid Leukemia or Myelodysplastic Syndrome

NCT02676323
View directory record Official record
Conditions
Acute Myeloid Leukemia, Myelodysplastic Syndrome
Interventions
Panobinostat, Fludarabine, Cytarabine, Intrathecal Triples, Leucovorin
Drug
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
Up to 24 Years
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
7
States / cities
Los Angeles, California • Palo Alto, California • San Diego, California + 4 more
Source: ClinicalTrials.gov public record
Updated Nov 13, 2018 · Synced Sep 1, 2026, 7:24 PM EDT
Completed Phase 1 Interventional

Panobinostat and Everolimus in Treating Patients With Relapsed or Refractory Lymphoma or Multiple Myeloma

NCT00962507
View directory record Official record
Conditions
Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm
Interventions
everolimus, panobinostat, laboratory biomarker analysis, pharmacological study
Drug · Other
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
2
States / cities
Duarte, California • Pasadena, California
Source: ClinicalTrials.gov public record
Updated Feb 14, 2013 · Synced Sep 1, 2026, 7:24 PM EDT
Completed Phase 2 Interventional Results available

Efficacy and Safety of Panobinostat (LBH589) in Patients With Refractory de Novo or Secondary Acute Myelogenous Leukemia (AML)

NCT00880269
View directory record Official record
Conditions
Refractory Leukemia, Acute Myelogenous Leukemia
Interventions
Panobinostat/LBH589
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 85 Years
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
7
States / cities
Chicago, Illinois • Omaha, Nebraska • Manhasset, New York + 4 more
Source: ClinicalTrials.gov public record
Updated Feb 22, 2017 · Synced Sep 1, 2026, 7:24 PM EDT
Terminated Phase 2 Interventional

A Study of Panobinostat in Pediatric Patients With Solid Tumors Including MRT/ATRT

NCT04897880
View directory record Official record
Conditions
Rhabdoid Tumor, Atypical Teratoid/Rhabdoid Tumor, Malignant Rhabdoid Tumor, Recurrent Brain Tumor, Childhood
Interventions
Panobinostat
Drug
Lead sponsor
Australian & New Zealand Children's Haematology/Oncology Group
Other
Eligibility
Up to 39 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 23, 2025 · Synced Sep 1, 2026, 7:24 PM EDT
Completed Phase 1 Interventional

A Trial l of Panobinostat Given in Combination With Trastuzumab and Paclitaxel in Adult Female Patients With HER2 Positive Metastatic Breast Cancer

NCT00788931
View directory record Official record
Conditions
HER-2 Positive Breast Cancer, Metastatic Breast Cancer
Interventions
IV LBH589, Oral LBH589, trastuzumab, paclitaxel
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older · Female only
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2008
U.S. locations
1
States / cities
Mobile, Alabama
Source: ClinicalTrials.gov public record
Updated Dec 18, 2020 · Synced Sep 1, 2026, 7:24 PM EDT
Completed Phase 1 Interventional

Panobinostat and Epirubicin in Treating Patients With Metastatic Malignant Solid Tumors

NCT00878904
View directory record Official record
Conditions
Unspecified Adult Solid Tumor, Protocol Specific
Interventions
epirubicin hydrochloride, panobinostat, gene expression analysis, protein expression analysis, western blotting, immunologic technique, laboratory biomarker analysis, pharmacological study
Drug · Genetic · Other
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 120 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2016
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Mar 23, 2017 · Synced Sep 1, 2026, 7:24 PM EDT
Completed Early Phase 1 Interventional

Infusion of Panobinostat (MTX110) Into the Fourth Ventricle in Children and Adults with Recurrent Medulloblastoma

NCT04315064
View directory record Official record
Conditions
Medulloblastoma
Interventions
Treatment with MTX110
Drug
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
1 Year to 80 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 9, 2025 · Synced Sep 1, 2026, 7:24 PM EDT
Terminated Phase 2 Interventional Results available

Oral LBH589 in Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) and Mantle Cell Lymphoma (MCL)

NCT01090973
View directory record Official record
Conditions
Non-Hodgkin's Lymphoma
Interventions
LBH589
Drug
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Dec 15, 2013 · Synced Sep 1, 2026, 7:24 PM EDT
Completed Phase 2 Interventional Results available

LBH589 Treatment for Refractory Clear Cell Renal Carcinoma

NCT00550277
View directory record Official record
Conditions
Renal Cell Carcinoma
Interventions
LBH589
Drug
Lead sponsor
SCRI Development Innovations, LLC
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
10
States / cities
Fort Myers, Florida • Gainesville, Georgia • Baton Rouge, Louisiana + 7 more
Source: ClinicalTrials.gov public record
Updated Nov 22, 2021 · Synced Sep 1, 2026, 7:24 PM EDT
Terminated Phase 1 Interventional

Carboplatin and Etoposide Plus LBH589 for Small Cell Lung Cancer

NCT00958022
View directory record Official record
Conditions
Small Cell Lung Cancer
Interventions
LBH589 and carboplatin with etoposide
Drug
Lead sponsor
Ahmad Tarhini
Other
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 21, 2017 · Synced Sep 1, 2026, 7:24 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

Re-expression of ER in Triple Negative Breast Cancers

NCT01194908
View directory record Official record
Conditions
Breast Cancer, Breast Tumors, Breast Neoplasms
Interventions
Decitabine, LBH589, Tamoxifen
Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Jan 25, 2015 · Synced Sep 1, 2026, 7:24 PM EDT
Completed Phase 1Phase 2 Interventional Results available

MTX110 by Convection-Enhanced Delivery in Treating Participants With Newly-Diagnosed Diffuse Intrinsic Pontine Glioma

NCT03566199
View directory record Official record
Conditions
Diffuse Intrinsic Pontine Glioma
Interventions
Panobinostat Nanoparticle Formulation MTX110, Convection-Enhanced Delivery (CED)
Drug
Lead sponsor
Sabine Mueller, MD, PhD
Other
Eligibility
2 Years to 21 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Feb 24, 2022 · Synced Sep 1, 2026, 7:24 PM EDT
Completed Phase 2 Interventional Results available

Panobinostat, Gemcitabine Hydrochloride, Busulfan, and Melphalan Before Stem Cell Transplant in Treating Patients With Refractory or Relapsed Multiple Myeloma

NCT02506959
View directory record Official record
Conditions
Plasma Cell Leukemia, Plasmacytoma, Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma
Interventions
Autologous Hematopoietic Stem Cell Transplantation, Busulfan, Gemcitabine Hydrochloride, Melphalan, Panobinostat, Peripheral Blood Stem Cell Transplantation, Pharmacological Study
Procedure · Drug · Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years to 65 Years
Enrollment
83 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2024
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 17, 2025 · Synced Sep 1, 2026, 7:24 PM EDT